VISEN Pharmaceuticals
2561.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.02B
Close$
$5.16
71.8% downside
Current Fair Value
71.8% downsideOvervalued by 71.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.02 Billion |
|---|---|
| Enterprise Value | $1.69 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.38 |
| Beta | 0.87 |
| Outstanding Shares | 109,582,105 |
Return
| Return on Equity | -35.68% |
|---|---|
| Return on Assets | -27.00% |
| Return on Invested Capital | -34.98% |
Valuation & Multiples
| P/E Ratio | -7.17 |
|---|---|
| PEG | 60.81 |
| Price to Sales | - |
| Price to Book Ratio | 3.05 |
| Enterprise Value to Revenue | 82.9 |
| Enterprise Value to EBIT | -7.16 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About VISEN Pharmaceuticals
82 employees
CEO: An-bang Lu VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offe...